Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Dr. Yvonne Greenstreet Appointed as an Independent Member of the Moelis & Company Board of Directors

MC

Moelis & Company (NYSE: MC), a leading global independent investment bank, today announced the appointment of Dr. Yvonne Greenstreet as an independent member of the Board of Directors.

Dr. Greenstreet has over 20 years of experience in the pharmaceutical industry and has held senior roles in research and development, strategy, commercial development and portfolio management. She was formerly Senior Vice President and Head of Medicines Development for Pfizer where she was a member of the Specialty Business global executive team. Dr. Greenstreet also spent 18 years at GlaxoSmithKline, most recently as Senior Vice President and Chief of Strategy for Research and Development and a member of the corporate portfolio management board. She held a variety of positions at GlaxoSmithKline prior to this, including Chief Medical Officer for Europe.

Ken Moelis, Chairman and CEO of Moelis & Company, said, “Yvonne’s wealth of experience in the pharmaceutical industry and her proven track record as a highly regarded business leader will greatly benefit our Firm and our clients. We are delighted to welcome her as Moelis & Company’s newest Board member.”

Dr. Greenstreet currently serves on the Board of Directors of Pacira Pharmaceuticals, a specialty pharmaceutical company focused on the development of products for postsurgical pain control, the Board of Directors of Advanced Accelerator Applications, a radiopharmaceutical company that develops diagnostic and therapeutic products, and the Board of Directors of Indivior, a pharmaceutical company that develops products to treat addiction. She is also a member of the Scientific Advisory Board of the Bill & Melinda Gates Foundation.

Dr. Greenstreet holds a Bachelor of Medicine, Bachelor of Surgery from the University of Leeds, United Kingdom, and an M.B.A. from INSEAD, France.

About Moelis & Company

Moelis & Company is a leading global independent investment bank that provides innovative strategic advice and solutions to a diverse client base, including corporations, governments and financial sponsors. The Firm assists its clients in achieving their strategic goals by offering comprehensive integrated financial advisory services across all major industry sectors. Moelis & Company’s experienced professionals advise clients on their most critical decisions, including mergers and acquisitions, recapitalizations and restructurings and other corporate finance matters. The Firm serves its clients with 550 employees based in 17 offices in North and South America, Europe, the Middle East, Asia and Australia. For further information, please visit: www.moelis.com.

Media:
Moelis & Company
Andrea Hurst
T: + 1 212 883 3666
M: + 1 347 583 9705
andrea.hurst@moelis.com
or
Investor:
Moelis & Company
Kate Pilcher Ciafone
T: + 1 212 883 3807
kate.ciafone@moelis.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today